Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

The "Sinusitis Pipeline Insight Analysis Report" drug pipelines has been added to ResearchAndMarkets.com's offering.The sinusitis treatment pipeline analysis provides an overview of recent ...

The leading Advanced Melanoma Companies such as OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis ...

The Global Viral Vector Market was valued at approximately USD 3.10 billion in 2022 and is projected to grow at a robust CAGR of more than 11.5% during the forecast period 2023-2030. Read the Market ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

A new study led by researchers from Boston University Chobanian & Avedisian School of Medicine has found there is no consensus in how clinical experts interpret CGM reports from people without ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...